Loading...

David Cheresh

TitleProfessor
InstitutionUniversity of California San Diego
DepartmentPathology
Address9500 Gilman Drive #0695
La Jolla CA 92093
Phone858-822-2232
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Targeting a non-canonical RAS-driven pathway in pancreatic cancer
    NIH/NCI R01CA168692Jul 1, 2012 - Apr 30, 2017
    Role: Principal Investigator
    MicroRNA regulation of RasGAP's during angiogenesis
    NIH/NHLBI R01HL103956Jun 15, 2011 - May 31, 2016
    Role: Principal Investigator
    Identification of novel pancreatic cancer biomarkers
    NIH/NCI R21CA129660Sep 1, 2007 - Aug 31, 2009
    Role: Principal Investigator
    Endothelial Barrier Function Regulation by VEGF
    NIH/NHLBI R01HL078912Aug 1, 2005 - Jul 31, 2010
    Role: Principal Investigator
    Targeting Vessels in Tumors
    NIH P01CA104898May 16, 2005 - Aug 31, 2011
    Role: Co-Investigator
    Biological Response to the Extracellular Matrix
    NIH/NCI R13CA094245Apr 1, 2002 - Dec 31, 2002
    Role: Principal Investigator
    Regulation of cell invasion by apoptotic mechanisms
    NIH/NCI R01CA095262Mar 1, 2002 - May 31, 2012
    Role: Principal Investigator
    Angiogenesis and Mircrocirculation Conference
    NIH/NCI R13CA092869Jun 1, 2001 - May 31, 2002
    Role: Principal Investigator
    VASCULAR CELL BIOLOGY CONFERENCE
    NIH/NHLBI R13HL065737Aug 1, 2000 - Jul 31, 2001
    Role: Principal Investigator
    Combinatorial Chemistry and Cancer Target
    NIH P01CA078045May 7, 1998 - Feb 28, 2010
    Role: Co-Investigator
    Integrin Signaling in Hemostasis and Blood Diseases
    NIH/NHLBI P01HL057900Apr 1, 1997 - Jan 31, 2014
    Role: Co-Investigator
    VASCULAR INTEGRIN IN ANGIOGENESIS OF BREAST CANCER
    NIH/NHLBI R01HL054444Jun 1, 1995 - May 31, 1999
    Role: Principal Investigator
    CRAF-mediated vascular resistance to cancer therapies
    NIH/NCI R01CA050286Aug 1, 1989 - Feb 29, 2020
    Role: Principal Investigator
    VEGF and PDGF in angiogenesis and tumor progression
    NIH/NCI R37CA050286Aug 1, 1989 - Apr 30, 2014
    Role: Principal Investigator
    Integrin alpha v beta 3 promotes resistance to EGF receptor inhibitors
    NIH/NCI R01CA045726Apr 1, 1988 - Jan 31, 2018
    Role: Principal Investigator
    PROPERTIES OF MELANOMA CELL SURFACE GLYCOLIPIDS
    NIH/NCI F32CA007544Mar 1, 1985
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Wang H, Lapek J, Fujimura K, Strnadel J, Liu B, Gonzalez DJ, Zhang W, Watson F, Yu V, Liu C, Melo CM, Miller YI, Elliott KC, Cheresh D, Klemke RL. Pseudopodium-enriched atypical kinase 1 mediates angiogenesis by modulating GATA2-dependent VEGFR2 transcription. Cell Discov. 2018; 4:26. PMID: 29872538.
      View in: PubMed
    2. Cosset É, Weis SM, Cheresh D. Re-thinking the preclinical development of GBM therapeutics. Oncoscience. 2018 Jan; 5(1-2):11-12. PMID: 29556513.
      View in: PubMed
    3. Sun Q, Lesperance J, Wettersten H, Luterstein E, DeRose YS, Welm A, Cheresh D, Desgrosellier JS. Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis. J Clin Invest. 2018 Jan 02; 128(1):531-544. PMID: 29227280.
      View in: PubMed
    4. Cosset É, Ilmjärv S, Dutoit V, Elliott K, von Schalscha T, Camargo MF, Reiss A, Moroishi T, Seguin L, Gomez G, Moo JS, Preynat-Seauve O, Krause KH, Chneiweiss H, Sarkaria JN, Guan KL, Dietrich PY, Weis SM, Mischel PS, Cheresh D. Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. Cancer Cell. 2017 Dec 11; 32(6):856-868.e5. PMID: 29198914.
      View in: PubMed
    5. Seguin L, Camargo MF, Wettersten HI, Kato S, Desgrosellier JS, von Schalscha T, Elliott KC, Cosset E, Lesperance J, Weis SM, Cheresh D. Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. Cancer Discov. 2017 12; 7(12):1464-1479. PMID: 28893801.
      View in: PubMed
    6. Hazell AS, Afadlal S, Cheresh D, Azar A. Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke's encephalopathy. Neurosci Lett. 2017 Mar 06; 642:163-167. PMID: 28109775.
      View in: PubMed
    7. Wilson R, Espinosa-Diez C, Kanner N, Chatterjee N, Ruhl R, Hipfinger C, Advani SJ, Li J, Khan OF, Franovic A, Weis SM, Kumar S, Coussens LM, Anderson DG, Chen CC, Cheresh D, Anand S. MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment. Nat Commun. 2016 Nov 25; 7:13597. PMID: 27886180.
      View in: PubMed
    8. Advani SJ, Camargo MF, Seguin L, Mielgo A, Anand S, Hicks AM, Aguilera J, Franovic A, Weis SM, Cheresh D. Kinase-independent role for CRAF-driving tumour radioresistance via CHK2. Nat Commun. 2015 Sep 03; 6:8154. PMID: 26333361; PMCID: PMC4559870.
    9. Franovic A, Elliott KC, Seguin L, Camargo MF, Weis SM, Cheresh D. Glioblastomas require integrin avß3/PAK4 signaling to escape senescence. Cancer Res. 2015 Nov 01; 75(21):4466-73. PMID: 26297735; PMCID: PMC4631634 [Available on 11/01/16].
    10. Acevedo LM, Lindquist JN, Walsh BM, Sia P, Cimadamore F, Chen C, Denzel M, Pernia CD, Ranscht B, Terskikh A, Snyder EY, Cheresh D. hESC Differentiation toward an Autonomic Neuronal Cell Fate Depends on Distinct Cues from the Co-Patterning Vasculature. Stem Cell Reports. 2015 Jun 09; 4(6):1075-88. PMID: 26004631; PMCID: PMC4471822.
    11. Seguin L, Desgrosellier JS, Weis SM, Cheresh D. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015 Apr; 25(4):234-40. PMID: 25572304; PMCID: PMC4380531.
    12. Desgrosellier JS, Lesperance J, Seguin L, Gozo M, Kato S, Franovic A, Yebra M, Shattil SJ, Cheresh D. Integrin avß3 drives slug activation and stemness in the pregnant and neoplastic mammary gland. Dev Cell. 2014 Aug 11; 30(3):295-308. PMID: 25117682; PMCID: PMC4147869.
    13. Seguin L, Gozo M, Weis SM, Cheresh D. Targeting the Achilles' heel of drug-resistant cancer stem cells. Cell Cycle. 2014; 13(13):2017-8. PMID: 24906000; PMCID: PMC4111689.
    14. Seguin L, Weis SM, Cheresh D. Variety in the tumor microenvironment: integrin splicing regulates stemness. Cell Stem Cell. 2014 May 01; 14(5):557-8. PMID: 24792112.
      View in: PubMed
    15. Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM, Cheresh D. An integrin ß3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014 May; 16(5):457-68. PMID: 24747441.
      View in: PubMed
    16. Jean C, Chen XL, Nam JO, Tancioni I, Uryu S, Lawson C, Ward KK, Walsh CT, Miller NL, Ghassemian M, Turowski P, Dejana E, Weis S, Cheresh D, Schlaepfer DD. Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function. J Cell Biol. 2014 Jan 20; 204(2):247-63. PMID: 24446483; PMCID: PMC3897185.
    17. Cheresh D, Stupack DG. Tumor angiogenesis: putting a value on plastic GEMMs. Circ Res. 2014 Jan 03; 114(1):9-11. PMID: 24385501; PMCID: PMC4090242.
    18. Westenskow PD, Kurihara T, Aguilar E, Scheppke EL, Moreno SK, Wittgrove C, Marchetti V, Michael IP, Anand S, Nagy A, Cheresh D, Friedlander M. Ras pathway inhibition prevents neovascularization by repressing endothelial cell sprouting. J Clin Invest. 2013 Nov; 123(11):4900-8. PMID: 24084735; PMCID: PMC3809796.
    19. Han J, Zhang G, Welch EJ, Liang Y, Fu J, Vogel SM, Lowell CA, Du X, Cheresh D, Malik AB, Li Z. A critical role for Lyn kinase in strengthening endothelial integrity and barrier function. Blood. 2013 Dec 12; 122(25):4140-9. PMID: 24108461; PMCID: PMC3862279.
    20. Weis SM, Cheresh D. A wake-up call for hibernating tumour cells. Nat Cell Biol. 2013 Jul; 15(7):721-3. PMID: 23817234.
      View in: PubMed
    21. Garmy-Susini B, Avraamides CJ, Desgrosellier JS, Schmid MC, Foubert P, Ellies LG, Lowy AM, Blair SL, Vandenberg SR, Datnow B, Wang HY, Cheresh D, Varner J. PI3Ka activates integrin a4ß1 to establish a metastatic niche in lymph nodes. Proc Natl Acad Sci U S A. 2013 May 28; 110(22):9042-7. PMID: 23671068.
      View in: PubMed
    22. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh D, Park M, Bergers G. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell. 2012 Jul 10; 22(1):21-35. PMID: 22789536; PMCID: PMC4068350.
    23. Lim ST, Miller NL, Chen XL, Tancioni I, Walsh CT, Lawson C, Uryu S, Weis SM, Cheresh D, Schlaepfer DD. Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression. J Cell Biol. 2012 Jun 25; 197(7):907-19. PMID: 22734001; PMCID: PMC3384409.
    24. Lau SK, Shields DJ, Murphy EA, Desgrosellier JS, Anand S, Huang M, Kato S, Lim ST, Weis SM, Stupack DG, Schlaepfer DD, Cheresh D. EGFR-mediated carcinoma cell metastasis mediated by integrin avß5 depends on activation of c-Src and cleavage of MUC1. PLoS One. 2012; 7(5):e36753. PMID: 22586492; PMCID: PMC3346745.
    25. Yu PT, Babicky M, Jaquish D, French R, Marayuma K, Mose E, Niessen S, Hoover H, Shields D, Cheresh D, Cravatt BF, Lowy AM. The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome. Int J Cancer. 2012 Oct 15; 131(8):1744-54. PMID: 22275185; PMCID: PMC3424378.
    26. Chen XL, Nam JO, Jean C, Lawson C, Walsh CT, Goka E, Lim ST, Tomar A, Tancioni I, Uryu S, Guan JL, Acevedo LM, Weis SM, Cheresh D, Schlaepfer DD. VEGF-induced vascular permeability is mediated by FAK. Dev Cell. 2012 Jan 17; 22(1):146-57. PMID: 22264731; PMCID: PMC3266538.
    27. Anand S, Cheresh D. Emerging Role of Micro-RNAs in the Regulation of Angiogenesis. Genes Cancer. 2011 Dec; 2(12):1134-8. PMID: 22866204; PMCID: PMC3411126.
    28. Scheppke L, Murphy EA, Zarpellon A, Hofmann JJ, Merkulova A, Shields DJ, Weis SM, Byzova TV, Ruggeri ZM, Iruela-Arispe ML, Cheresh D. Notch promotes vascular maturation by inducing integrin-mediated smooth muscle cell adhesion to the endothelial basement membrane. Blood. 2012 Mar 01; 119(9):2149-58. PMID: 22134168; PMCID: PMC3311249.
    29. Reardon DA, Cheresh D. Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer. 2011 Dec; 2(12):1159-65. PMID: 22866207; PMCID: PMC3411133.
    30. Cheresh D. Monographs editor. Genes Cancer. 2011 Dec; 2(12):1071. PMID: 22866197; PMCID: PMC3411130.
    31. Mielgo A, Seguin L, Huang M, Camargo MF, Anand S, Franovic A, Weis SM, Advani SJ, Murphy EA, Cheresh D. A MEK-independent role for CRAF in mitosis and tumor progression. Nat Med. 2011 Nov 13; 17(12):1641-5. PMID: 22081024; PMCID: PMC3233644.
    32. Weis SM, Cheresh D. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011 Nov 07; 17(11):1359-70. PMID: 22064426.
      View in: PubMed
    33. Weis SM, Cheresh D. aV integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med. 2011 Sep; 1(1):a006478. PMID: 22229119; PMCID: PMC3234453.
    34. Russell RC, Sufan RI, Zhou B, Heir P, Bunda S, Sybingco SS, Greer SN, Roche O, Heathcote SA, Chow VW, Boba LM, Richmond TD, Hickey MM, Barber DL, Cheresh D, Simon MC, Irwin MS, Kim WY, Ohh M. Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nat Med. 2011 Jun 19; 17(7):845-53. PMID: 21685897; PMCID: PMC3221316.
    35. Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG, Acevedo LM, Manglicmot JR, Song X, Wrasidlo W, Blair SL, Ginsberg MH, Cheresh D, Hirsch E, Field SJ, Varner JA. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3k?, a single convergent point promoting tumor inflammation and progression. Cancer Cell. 2011 Jun 14; 19(6):715-27. PMID: 21665146; PMCID: PMC3144144.
    36. Aspinall RJ, Weis SM, Barnes L, Lutu-Fuga K, Bylund DJ, Pockros PJ, Cheresh D. A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth factor levels. Liver Int. 2011 Sep; 31(8):1222-30. PMID: 21745297; PMCID: PMC3337519.
    37. Anand S, Cheresh D. MicroRNA-mediated regulation of the angiogenic switch. Curr Opin Hematol. 2011 May; 18(3):171-6. PMID: 21423013; PMCID: PMC3159578.
    38. Murphy EA, Majeti BK, Mukthavaram R, Acevedo LM, Barnes LA, Cheresh D. Targeted nanogels: a versatile platform for drug delivery to tumors. Mol Cancer Ther. 2011 Jun; 10(6):972-82. PMID: 21518727; PMCID: PMC3112300.
    39. Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L, Huang M, Shields DJ, Lindquist JN, Lapinski PE, King PD, Weis SM, Cheresh D. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med. 2010 Aug; 16(8):909-14. PMID: 20676106; PMCID: PMC3094020.
    40. Garmy-Susini B, Avraamides CJ, Schmid MC, Foubert P, Ellies LG, Barnes L, Feral C, Papayannopoulou T, Lowy A, Blair SL, Cheresh D, Ginsberg M, Varner JA. Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res. 2010 Apr 15; 70(8):3042-51. PMID: 20388801; PMCID: PMC2856096.
    41. Lindquist JN, Cheresh D, Snyder EY. Derivation of vasculature from embryonic stem cells. Curr Protoc Stem Cell Biol. 2010 Mar; Chapter 1:Unit 1F.9. PMID: 20200855.
      View in: PubMed
    42. Murphy EA, Shields DJ, Stoletov K, Dneprovskaia E, McElroy M, Greenberg JI, Lindquist J, Acevedo LM, Anand S, Majeti BK, Tsigelny I, Saldanha A, Walsh B, Hoffman RM, Bouvet M, Klemke RL, Vogt PK, Arnold L, Wrasidlo W, Cheresh D. Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Proc Natl Acad Sci U S A. 2010 Mar 02; 107(9):4299-304. PMID: 20154271; PMCID: PMC2840076.
    43. Desgrosellier JS, Cheresh D. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010 Jan; 10(1):9-22. PMID: 20029421; PMCID: PMC4383089.
    44. Shields DJ, Niessen S, Murphy EA, Mielgo A, Desgrosellier JS, Lau SK, Barnes LA, Lesperance J, Bouvet M, Tarin D, Cravatt BF, Cheresh D. RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia. Proc Natl Acad Sci U S A. 2010 Feb 02; 107(5):2189-94. PMID: 20080647; PMCID: PMC2836678.
    45. Greenberg JI, Cheresh D. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. Expert Opin Biol Ther. 2009 Nov; 9(11):1347-56. PMID: 19761418.
      View in: PubMed
    46. Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prévost N, Tarin D, Shattil SJ, Cheresh D. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med. 2009 Oct; 15(10):1163-9. PMID: 19734908; PMCID: PMC2759406.
    47. Koh W, Sachidanandam K, Stratman AN, Sacharidou A, Mayo AM, Murphy EA, Cheresh D, Davis GE. Formation of endothelial lumens requires a coordinated PKCepsilon-, Src-, Pak- and Raf-kinase-dependent signaling cascade downstream of Cdc42 activation. J Cell Sci. 2009 Jun 01; 122(Pt 11):1812-22. PMID: 19435802; PMCID: PMC2684834.
    48. Weis SM, Stupack DG, Cheresh D. Agonizing integrin antagonists? Cancer Cell. 2009 May 05; 15(5):359-61. PMID: 19411065.
      View in: PubMed
    49. Makale M, McElroy M, O'Brien P, Hoffman RM, Guo S, Bouvet M, Barnes L, Ingulli E, Cheresh D. Extended-working-distance multiphoton micromanipulation microscope for deep-penetration imaging in live mice and tissue. J Biomed Opt. 2009 Mar-Apr; 14(2):024032. PMID: 19405761; PMCID: PMC3098575.
    50. Ricono JM, Huang M, Barnes LA, Lau SK, Weis SM, Schlaepfer DD, Hanks SK, Cheresh D. Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res. 2009 Feb 15; 69(4):1383-91. PMID: 19208836; PMCID: PMC2741736.
    51. Acevedo LM, Cheresh D. Suppressing NFAT increases VEGF signaling in hemangiomas. Cancer Cell. 2008 Dec 09; 14(6):429-30. PMID: 19061833.
      View in: PubMed
    52. Doukas J, Eide L, Stebbins K, Racanelli-Layton A, Dellamary L, Martin M, Dneprovskaia E, Noronha G, Soll R, Wrasidlo W, Acevedo LM, Cheresh D. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2009 Mar; 328(3):758-65. PMID: 19056934.
      View in: PubMed
    53. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, Scheppke L, Stockmann C, Johnson RS, Angle N, Cheresh D. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008 Dec 11; 456(7223):809-13. PMID: 18997771; PMCID: PMC2605188.
    54. Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, Cheresh D, Johnson RS. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature. 2008 Dec 11; 456(7223):814-8. PMID: 18997773; PMCID: PMC3103772.
    55. Rupp PA, Visconti RP, Czirók A, Cheresh D, Little CD. Matrix metalloproteinase 2-integrin alpha(v)beta3 binding is required for mesenchymal cell invasive activity but not epithelial locomotion: a computational time-lapse study. Mol Biol Cell. 2008 Dec; 19(12):5529-40. PMID: 18923152; PMCID: PMC2592652.
    56. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, Wrasidlo W, Cheresh D. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A. 2008 Jul 08; 105(27):9343-8. PMID: 18607000; PMCID: PMC2453735.
    57. Scheppke L, Aguilar E, Gariano RF, Jacobson R, Hood J, Doukas J, Cao J, Noronha G, Yee S, Weis S, Martin MB, Soll R, Cheresh D, Friedlander M. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest. 2008 Jun; 118(6):2337-46. PMID: 18483622; PMCID: PMC2381746.
    58. Serban D, Leng J, Cheresh D. H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors. Circ Res. 2008 Jun 06; 102(11):1350-8. PMID: 18467631; PMCID: PMC2743877.
    59. Weis SM, Lim ST, Lutu-Fuga KM, Barnes LA, Chen XL, Göthert JR, Shen TL, Guan JL, Schlaepfer DD, Cheresh D. Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. J Cell Biol. 2008 Apr 07; 181(1):43-50. PMID: 18391070; PMCID: PMC2287283.
    60. Acevedo LM, Weis SM, Cheresh D. Robo4 counteracts VEGF signaling. Nat Med. 2008 Apr; 14(4):372-3. PMID: 18391935.
      View in: PubMed
    61. Acevedo LM, Barillas S, Weis SM, Göthert JR, Cheresh D. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood. 2008 Mar 01; 111(5):2674-80. PMID: 18180379; PMCID: PMC2254547.
    62. Cheresh D. Preface: a tribute to Dr. Judah Folkman. Methods Enzymol. 2008; 443:xv-xvi. PMID: 18772007.
      View in: PubMed
    63. Yang XL, Kapoor M, Otero FJ, Slike BM, Tsuruta H, Frausto R, Bates A, Ewalt KL, Cheresh D, Schimmel P. Gain-of-function mutational activation of human tRNA synthetase procytokine. Chem Biol. 2007 Dec; 14(12):1323-33. PMID: 18096501; PMCID: PMC2693404.
    64. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh D, Karin M. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature. 2007 Apr 05; 446(7136):690-4. PMID: 17377533.
      View in: PubMed
    65. Alavi AS, Acevedo L, Min W, Cheresh D. Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. Cancer Res. 2007 Mar 15; 67(6):2766-72. PMID: 17363598.
      View in: PubMed
    66. Doukas J, Wrasidlo W, Noronha G, Dneprovskaia E, Fine R, Weis S, Hood J, Demaria A, Soll R, Cheresh D. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci U S A. 2006 Dec 26; 103(52):19866-71. PMID: 17172449; PMCID: PMC1702529.
    67. Weis SM, Lindquist JN, Barnes LA, Lutu-Fuga KM, Cui J, Wood MR, Cheresh D. Cooperation between VEGF and beta3 integrin during cardiac vascular development. Blood. 2007 Mar 01; 109(5):1962-70. PMID: 17062734; PMCID: PMC1801042.
    68. Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ, Lahti JM, Cheresh D. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature. 2006 Jan 05; 439(7072):95-9. PMID: 16397500.
      View in: PubMed
    69. Weis SM, Cheresh D. Pathophysiological consequences of VEGF-induced vascular permeability. Nature. 2005 Sep 22; 437(7058):497-504. PMID: 16177780.
      View in: PubMed
    70. Potter MD, Barbero S, Cheresh D. Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and beta-catenin and maintains the cellular mesenchymal state. J Biol Chem. 2005 Sep 09; 280(36):31906-12. PMID: 16027153.
      View in: PubMed
    71. Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol. 2004 Oct 25; 167(2):223-9. PMID: 15504909; PMCID: PMC2172541.
    72. Stupack DG, Cheresh D. A Bit-role for integrins in apoptosis. Nat Cell Biol. 2004 May; 6(5):388-9. PMID: 15122265.
      View in: PubMed
    73. Weis S, Shintani S, Weber A, Kirchmair R, Wood M, Cravens A, McSharry H, Iwakura A, Yoon YS, Himes N, Burstein D, Doukas J, Soll R, Losordo D, Cheresh D. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest. 2004 Mar; 113(6):885-94. PMID: 15067321; PMCID: PMC362122.
    74. McDonald DM, Teicher BA, Stetler-Stevenson W, Ng SS, Figg WD, Folkman J, Hanahan D, Auerbach R, O'Reilly M, Herbst R, Cheresh D, Gordon M, Eggermont A, Libutti SK. Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring. J Immunother. 2004 Mar-Apr; 27(2):161-75. PMID: 14770088.
      View in: PubMed
    75. Stupack DG, Cheresh D. Apoptotic cues from the extracellular matrix: regulators of angiogenesis. Oncogene. 2003 Dec 08; 22(56):9022-9. PMID: 14663480.
      View in: PubMed
    76. Hood JD, Frausto R, Kiosses WB, Schwartz MA, Cheresh D. Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol. 2003 Sep 01; 162(5):933-43. PMID: 12952943; PMCID: PMC2172815.
    77. Hood JD, Cheresh D. Building a better Trap. Proc Natl Acad Sci U S A. 2003 Jul 22; 100(15):8624-5. PMID: 12861079; PMCID: PMC166360.
    78. Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh D. Role of Raf in vascular protection from distinct apoptotic stimuli. Science. 2003 Jul 04; 301(5629):94-6. PMID: 12843393.
      View in: PubMed
    79. Hsia DA, Mitra SK, Hauck CR, Streblow DN, Nelson JA, Ilic D, Huang S, Li E, Nemerow GR, Leng J, Spencer KS, Cheresh D, Schlaepfer DD. Differential regulation of cell motility and invasion by FAK. J Cell Biol. 2003 Mar 03; 160(5):753-67. PMID: 12615911; PMCID: PMC2173366.
    80. Hauck CR, Hsia DA, Puente XS, Cheresh D, Schlaepfer DD. FRNK blocks v-Src-stimulated invasion and experimental metastases without effects on cell motility or growth. EMBO J. 2002 Dec 02; 21(23):6289-302. PMID: 12456636; PMCID: PMC136935.
    81. Stupack DG, Cheresh D. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci. 2002 Oct 01; 115(Pt 19):3729-38. PMID: 12235283.
      View in: PubMed
    82. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh D. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002 Jun 28; 296(5577):2404-7. PMID: 12089446.
      View in: PubMed
    83. Wakasugi K, Slike BM, Hood J, Ewalt KL, Cheresh D, Schimmel P. Induction of angiogenesis by a fragment of human tyrosyl-tRNA synthetase. J Biol Chem. 2002 Jun 07; 277(23):20124-6. PMID: 11956181.
      View in: PubMed
    84. Kiosses WB, Hood J, Yang S, Gerritsen ME, Cheresh D, Alderson N, Schwartz MA. A dominant-negative p65 PAK peptide inhibits angiogenesis. Circ Res. 2002 Apr 05; 90(6):697-702. PMID: 11934838.
      View in: PubMed
    85. Eliceiri BP, Puente XS, Hood JD, Stupack DG, Schlaepfer DD, Huang XZ, Sheppard D, Cheresh D. Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol. 2002 Apr 01; 157(1):149-60. PMID: 11927607; PMCID: PMC2173263.
    86. Nemerow GR, Cheresh D. Herpesvirus hijacks an integrin. Nat Cell Biol. 2002 Apr; 4(4):E69-71. PMID: 11944033.
      View in: PubMed
    87. Cheresh D, Stupack DG. Integrin-mediated death: an explanation of the integrin-knockout phenotype? Nat Med. 2002 Mar; 8(3):193-4. PMID: 11875466.
      View in: PubMed
    88. Strömblad S, Fotedar A, Brickner H, Theesfeld C, Aguilar de Diaz E, Friedlander M, Cheresh D. Loss of p53 compensates for alpha v-integrin function in retinal neovascularization. J Biol Chem. 2002 Apr 19; 277(16):13371-4. PMID: 11856728.
      View in: PubMed
    89. Stupack DG, Cheresh D. ECM remodeling regulates angiogenesis: endothelial integrins look for new ligands. Sci STKE. 2002 Feb 12; 2002(119):pe7. PMID: 11842241.
      View in: PubMed
    90. Hood JD, Cheresh D. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002 Feb; 2(2):91-100. PMID: 12635172.
      View in: PubMed
    91. Otani A, Slike BM, Dorrell MI, Hood J, Kinder K, Ewalt KL, Cheresh D, Schimmel P, Friedlander M. A fragment of human TrpRS as a potent antagonist of ocular angiogenesis. Proc Natl Acad Sci U S A. 2002 Jan 08; 99(1):178-83. PMID: 11773625; PMCID: PMC117535.
    92. Wakasugi K, Slike BM, Hood J, Otani A, Ewalt KL, Friedlander M, Cheresh D, Schimmel P. A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. Proc Natl Acad Sci U S A. 2002 Jan 08; 99(1):173-7. PMID: 11773626; PMCID: PMC117534.